AstraZeneca Patient Assistance Programs Provided More Than Half a Million Patients with Free Medicine in 2013

  AstraZeneca Patient Assistance Programs Provided More Than Half a Million
  Patients with Free Medicine in 2013

Business Wire

WILMINGTON, Del. -- February 20, 2014

AstraZeneca (NYSE:AZN) announced today that, in 2013, it provided nearly $975
million in savings to more than 567,000 patients in the United States through
its patient assistance programs. These programs include AZ&Me and the
MedImmune Assistance Program.

“At AstraZeneca, we work hard to understand the needs of patients, and we’re
committed to helping them afford their medications,” said Paul Hudson,
President, AstraZeneca U.S. and Executive Vice President, North America. “For
more than 35 years, our patient assistance programs have been helping people
access the medicines they need, and we look forward to bringing them continued
savings and benefits in 2014.”

AstraZeneca’s AZ&Me prescription savings programs are designed to help
qualifying people without insurance, those in Medicare Part D, those who
receive their medications through participating health care facilities, and
those who have faced a financial challenge recently.

  *Individuals without Prescription Drug Coverage: AstraZeneca provides free
    medicines to qualifying individuals with an annual income at or below
    $35,000 and families of four with an annual household income at or below
    $70,000.
  *Part D Beneficiaries: AstraZeneca provides free medicines to qualifying
    Medicare Part D beneficiaries with an annual income at or below $35,000
    and couples with an annual household income at or below $48,000.
  *Healthcare Facilities: AstraZeneca provides free medicines to qualifying
    non-profit organizations, such as disproportionate share hospitals,
    community health centers and community free clinics. This program helps
    provide medicines to qualifying patients at the time and place of
    treatment.

The MedImmune Assistance Program provides medication free of charge to
qualified patients who are uninsured, or who have been rendered uninsured by
their insurance company. Qualified patients must meet all eligibility
criteria.

Click here for a visual overview of AstraZeneca’s prescriptions savings
programs. For more detailed information about the AZ&Me prescription savings
programs, please visit www.astrazeneca-us.comor call 1-800-AZandMe
(292-6363). For additional information about the MedImmune Assistance Program,
visit www.myAccess360.com or call 1-877-778-9010.

AstraZeneca also participates in multi-manufacturer programs like the
Partnership for Prescription Assistance and supports other organizations with
the same goal—increasing access to medicines as well as health care.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that
focuses on the discovery, development and commercialization of prescription
medicines, primarily for the treatment of cardiovascular, metabolic,
respiratory, inflammation, autoimmune, oncology, infection and neuroscience
diseases. AstraZeneca operates in over 100 countries and its innovative
medicines are used by millions of patients worldwide.

For more information about AstraZeneca in the U.S. or our AZ&Me™ Prescription
Savings programs, please visit: www.astrazeneca-us.com or call 1-800-AZandMe
(292-6363).

Photos/Multimedia Gallery Available:
http://www.businesswire.com/multimedia/home/20140220005341/en/

Multimedia
Available:http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50808103&lang=en

Contact:

Media Inquiries:
AstraZeneca
Michele Meixell, 302-885-2677
Michele.Meixell@AstraZeneca.com
or
Alisha Martin, 302-885-2677
Alisha.Martin@AstraZeneca.com
 
Press spacebar to pause and continue. Press esc to stop.